A Study Comparing Sems Placement With and and Without Biliary Sphincterectomy in Patients With Malignant Biliary Obstruction
Primary Purpose
Bile Duct Obstruction
Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
ERCP
Sponsored by
About this trial
This is an interventional treatment trial for Bile Duct Obstruction focused on measuring Endoscopic retrograde cholangiopancreatography (ERCP), Distal malignant bile duct obstruction, Sphincterotomy
Eligibility Criteria
Inclusion Criteria:
- Patients referred for endoscopic retrograde cholangiopancreatography
- Malignant bile duct obstruction
- Signed written informed consent
- Age > 18
Exclusion Criteria:
- Inability to provide inform consent
- Pregnancy or lactation
- Suspected perforation of the GI tract
- Anatomical alterations due to previous surgery (Billroth surgery)
- Coagulation alterations
Sites / Locations
- Endoscopy Unit, Gastroenterology Department, Humanitas Research HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
A
B
Arm Description
ERCP with (Group A) ES before biliary SEMS placement
ERCP without (Group B) ES before biliary SEMS placement
Outcomes
Primary Outcome Measures
Number and type of complications after ERCP.
Secondary Outcome Measures
Full Information
NCT ID
NCT03628001
First Posted
April 3, 2018
Last Updated
September 19, 2022
Sponsor
Istituto Clinico Humanitas
1. Study Identification
Unique Protocol Identification Number
NCT03628001
Brief Title
A Study Comparing Sems Placement With and and Without Biliary Sphincterectomy in Patients With Malignant Biliary Obstruction
Official Title
A Prospective, Randomized, Multicenter Study Comparing Sems Placement With and and Without Biliary Sphincterectomy in Patients With Malignant Biliary Obstruction (ES vs noES-1)
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2015 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Istituto Clinico Humanitas
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Background and rationale Placement of biliary self expanding metal stent (SEMS) is indicated when malignant common bile duct obstruction is encountered.
Currently, there is still controversy regarding the use of endoscopic sphincterotomy (EST) before the placement of biliary stents. EST may facilitate insertion of self expandable metal stent (SEMS) and also help avert the development of pancreatitis from stent-related occlusion of the pancreatic duct. On the other hand, ES is also independently associated with pancreatitis, bleeding, and perforation.
Latest European guidelines indicate that EST is not necessary for inserting single plastic or metal biliary stents, nevertheless a more recent meta analysis showed that ES may decrease the rate of PEP.
Population and patient selection criteria All the patient referred for endoscopic retrograde cholangiopancreatography (ERCP) due to malignant bile duct obstruction.
Study design and study duration Prospective randomized, multicenter study. 18 months.
Description of study treatment/product/intervention All the patients will be randomly assigned to undergo ERCP with (Group A) or without (Group B) ES before biliary SEMS placement.
All the endoscopic procedures will be performed by experienced endoscopist in the endoscopy suite.
All the procedure will be conducted under deep sedation. SEMS placed will be fully covered.
Objectives To assess the need for EST before SEMS placement in patients with malignant bile duct obstruction.
To evaluate immediate (periprocedural) and delayed (30 days) post ERCP complications including pancreatitis, SEMS migration, bleeding and perforation.
Statistical methods, data analysis A sample size analysis to detect superiority at 5% significance level and a power of 80% showed that 500 patients had to be enrolled in each group.
Continuous variables such age will be reported in terms of their mean and range, and t-test will be done to test their main difference.
X square test or Fisher exact test will be carried out for statistical analysis to compare rates of total complications between the two groups and rates of pancreatitis, bleeding, stent migration and perforation.
Wilcoxon Mann-Withney test will be used for comparison of means between 2 continuous variables. A single-tailed P value of less than 0,05 is considered significant.
Study time table Project starting date: 15-7-2015 Project completion of patients accrual: 15-10-2016 Project completion of data collection: 15-11-2016 Project data analysis: 15-2-2017 Project presentation of scientific report: 15-4-2017
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bile Duct Obstruction
Keywords
Endoscopic retrograde cholangiopancreatography (ERCP), Distal malignant bile duct obstruction, Sphincterotomy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
400 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Other
Arm Description
ERCP with (Group A) ES before biliary SEMS placement
Arm Title
B
Arm Type
Other
Arm Description
ERCP without (Group B) ES before biliary SEMS placement
Intervention Type
Procedure
Intervention Name(s)
ERCP
Intervention Description
Pts will be randomized with or without sphinterectomy.
Primary Outcome Measure Information:
Title
Number and type of complications after ERCP.
Time Frame
18 Months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients referred for endoscopic retrograde cholangiopancreatography
Malignant bile duct obstruction
Signed written informed consent
Age > 18
Exclusion Criteria:
Inability to provide inform consent
Pregnancy or lactation
Suspected perforation of the GI tract
Anatomical alterations due to previous surgery (Billroth surgery)
Coagulation alterations
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andrea Anderloni, MD
Phone
0039-02-82247308
Email
andrea.anderloni@humanitas.it
First Name & Middle Initial & Last Name or Official Title & Degree
Alessandro Repici, MD
Phone
0039-02-82247493
Email
alessandro.repici@hunimed.eu
Facility Information:
Facility Name
Endoscopy Unit, Gastroenterology Department, Humanitas Research Hospital
City
Rozzano
State/Province
Milano
ZIP/Postal Code
20089
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alessandro Repici, MD
Phone
+390282247493
Email
alessadro.repici@humanitas.it
First Name & Middle Initial & Last Name & Degree
Alessandro Repici, MD
First Name & Middle Initial & Last Name & Degree
Roberta Maselli, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Study Comparing Sems Placement With and and Without Biliary Sphincterectomy in Patients With Malignant Biliary Obstruction
We'll reach out to this number within 24 hrs